Bavituximab Completed Phase 1 / 2 Trials for Hepatitis C Viral Infection Treatment

IndicationsStatusPurposePhase
CompletedTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT00343525Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C
NCT00128271Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection